Physician profile
Leigh Edwards
NPI 1962678037
$4,261.76
in general payments reported to CMS, 2019-2025
31 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $370 · 2021: $1,179 · 2022: $731 · 2023: $655 · 2024: $337 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.09 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,500.30 | 2019-2025 | Lo Loestrin Fe, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $819.17 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $351.65 | 2019-2025 | |
| Gynesonics, INC. | $175.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.18 | 2019-2022 | |
| Hologic Sales and Service, LLC | $162.60 | 2023-2025 | Novasure, Myosure Tissue Removal Device |
| Exeltis, USA INC. | $130.83 | 2021-2024 | Slynd |
| Novo Nordisk INC | $125.17 | 2019-2022 | |
| Organon LLC | $117.36 | 2022-2024 | Nexplanon |
| Medtronic, INC. | $91.66 | 2023 | Sonicision |
| Therapeuticsmd, INC. | $84.37 | 2019-2021 | |
| Davol INC. | $68.44 | 2022-2024 | Arista Ah Flexitip |
| Allergan, INC. | $56.86 | 2020 | |
| Amgen INC. | $50.78 | 2019-2020 | |
| Eisai INC. | $34.18 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $33.64 | 2020-2022 | |
| Minerva Surgical, INC | $32.41 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $32.14 | 2021-2024 | Contrave, Onzetra Xsail |
| Nalpropion Pharmaceuticals LLC | $26.21 | 2019 | |
| Evofem Biosciences, INC. | $26.02 | 2021 | |
| Zyla Life Sciences, INC. | $24.07 | 2020 | |
| Sumitomo Pharma America, INC. | $20.46 | 2024 | Myfembree |
| Biohaven Pharmaceutical Holding Company LTD. | $18.42 | 2022 | |
| Dexcom, INC. | $17.63 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $17.08 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.00 | 2019 | |
| Boston Scientific Corporation | $13.62 | 2019 | |
| Smith+Nephew, INC. | $12.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.77 | 2021 | |
| Merck Sharp & Dohme LLC | $11.42 | 2021 | |
| Lupin INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.